Editor Profile: Guest Editor of Special Column on Molecular Imaging and Theranostics

Dr. Wei Lu is a professor of School of Pharmacy at Fudan University, Shanghai, China. He received his Bachelor of pharmaceutical sciences in 2000 and Ph.D. of pharmaceutics in 2005 from Fudan University. After graduation, he worked as a lecturer at Fudan University (2005–2006). Dr. Lu took his post-doctoral training of molecular imaging at Department of Experimental Diagnostic Imaging, the University of Texas M.D. Anderson Cancer, USA (2006–2009) and was promoted to an instructor (2009–2010). He was then appointed as an assistant professor (tenure-track) of College of Pharmacy at the University of Rhode Island, USA (2010–2015) and was early promoted to an associate professor (tenured) in 2015. In the same year, Dr. Lu joined the faculty of Fudan University. Dr. Lu has a multidisciplinary research background in nanomedicine and gene/drug delivery. His Ph.D. work focused on nanoparticulate brain drug delivery for glioma gene therapy and chemotherapy. His research at M.D. Anderson Cancer Center focused on nanotechnology for cancer molecular imaging and therapeutics. Dr. Lu successfully developed hollow gold nanospheres as a platform nanotechnology for photothermal ablation therapy, siRNA delivery, and photoacoustic imaging. While photothermal ablation therapy represents an attractive therapeutic strategy, it is